Latest News and Press Releases

The first participants have been dosed in SAFYR, a Phase I clinical trial to test the safety and efficacy of two prophylactic vaccines developed with AstriVax technology.  The study will also provide...

Dr. Fanning brings a wealth of experience in creating infectious disease pipelines by internal R&D and licensing As the CBO of AstriVax, he will lead the company’s business development, including...

The government grant is awarded by Flanders Innovation & Entrepreneurship (VLAIO).The grant will be used to accelerate the development of the company’s therapeutic vaccine targeting chronic...

Dr. Mathieu Peeters brings an extensive clinical vaccine development track record from his senior roles at GSK Vaccines.Barbara Freitag joins AstriVax as an accomplished CFO in the biotech...

Christian Brander, Ph.D., is a leading expert on T cell responses to viral infections and brings an important blend of academic and biotech experience.Mala Maini, MD, Ph.D., is a professor of viral...

The government grant is awarded by Flanders Innovation & Entrepreneurship (VLAIO).The grant will be used to accelerate the company’s vaccine platform.  The non-dilutive financing builds upon the...

Emmanuel Hanon, PhD, will chair the company’s scientific advisory board. Professor Peter Piot (MD, PhD) and Professor Patrick Soentjens (MD, PhD) have been appointed as advisors. Together, they bring...

Dr Jeanne Bolger brings over 35 years of management experience in the pharmaceutical industry to the new Belgium-based vaccine technology company.Last month, AstriVax closed its funding round – led by...

KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform Closing on € 30 million, AstriVax has raised the largest amount of seed capital in the history of spin-offs linked...